Vericel Corporation (VCEL) Stock
Fundamentals
Recent news

Vericel Q2 Earnings Call Highlights
Vericel Q2 Earnings Call Highlights
VCEL

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
VCEL

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
VCEL

Vericel Q1 Earnings Call Highlights
Vericel Q1 Earnings Call Highlights
VCEL
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.14 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Vericel Q2 Earnings Call Highlights
Vericel Q2 Earnings Call Highlights
VCEL

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
VCEL

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
VCEL

Vericel Q1 Earnings Call Highlights
Vericel Q1 Earnings Call Highlights
VCEL

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
VCEL

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
VCEL

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates
Vericel Corporation (VCEL) Matches Q4 Earnings Estimates
VCEL

The 3 Highest-Rated Medical Stocks You Can Buy Today
The 3 Highest-Rated Medical Stocks You Can Buy Today
VCEL

3 Top Pharma Stocks for Investors Betting on a Biotech Boom
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
VCEL

Top Medical Stocks to Buy Amid Recent Market Volatility
Top Medical Stocks to Buy Amid Recent Market Volatility
VCEL
About Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director | 1964 |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer | 1976 |
| Mr. Michael Halpin | Chief Operating Officer | 1962 |
| Mr. Sean C. Flynn | Chief Legal Officer | 1974 |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 1962 |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller | — |
| Mr. Eric Burns | Vice President of Finance & Investor Relations | — |
| Mr. Roland DeAngelis | Chief Marketing Officer | — |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | — |
| Mr. Mike Gilligan | Senior Vice President of Sales | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.2 | -8.5 | -18.8 | +11.6 | ||||||||
| 2022 | -13.4 | +15.4 | -6.0 | -27.8 | -9.4 | -4.3 | +26.0 | -20.7 | -5.5 | +17.7 | -16.6 | +14.3 |
| 2023 | +9.3 | +7.2 | -2.2 | +7.1 | -0.3 | +15.0 | -4.0 | -6.5 | -1.1 | +6.0 | +1.5 | -0.0 |
| 2024 | +23.2 | +4.7 | +16.3 | -13.3 | +1.3 | -1.0 | +12.2 | +8.7 | -13.8 | +10.0 | +32.2 | -6.5 |
| 2025 | +6.2 | -13.2 | -9.9 | -11.8 | +8.9 | +5.2 | -16.0 | +2.0 | -9.0 | +13.4 | +9.6 | -7.2 |
| 2026 | +1.0 | -3.4 | -9.0 | +6.7 | -6.3 | +35.6 | +1.8 | -13.4 | -2.0 |



